Effects of fluoroquinolone restriction (from 2007 to 2012) on Clostridium difficile infections: interrupted time-series analysis

被引:38
作者
Sarma, J. B. [1 ]
Marshall, B. [1 ]
Cleeve, V. [1 ]
Tate, D. [1 ]
Oswald, T. [1 ]
Woolfrey, S. [2 ]
机构
[1] Northumbria Healthcare NHS Fdn Trust, Dept Microbiol, North Shields, Tyne & Wear, England
[2] Northumbria Healthcare NHS Fdn Trust, Dept Pharm, North Shields, Tyne & Wear, England
关键词
Antimicrobial stewardship; Clostridium difficile; Fluoroquinolones; Interrupted time-series analysis; HUMAN GUT MODEL; CHANGING EPIDEMIOLOGY; RISK-FACTORS; DIARRHEA; DISEASE; OUTBREAK;
D O I
10.1016/j.jhin.2015.05.013
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Antimicrobial stewardship is a key component in the reduction of healthcare-associated infections, particularly Clostridium difficile infection (CDI). We successfully restricted the use of cephalosporins and, subsequently, fluoroquinolones. From an endemically high level of >280 cases per year in 2007-08, the number of CDIs reduced to 72 cases in 2011-12. Aim: To describe the implementation and impact of fluoroquinolone restriction on CDI. Methods: This was an interrupted time-series analysis pre and post fluoroquinolone restriction for 60 months based on a Poisson distribution model. Findings: In June 2008, fluoroquinolone consumption halved to about 5 defined daily doses (DDD) per 100 occupied bed-days (OBD). This was followed by a significant fall in CDI number [ rate ratio (RR): 0.332; 95% confidence interval (CI): 0.240-0.460] which remained low over the subsequent months. Subsequently, fluoroquinolone consumption was further reduced to about 2 DDD/100 OBD in June 2010 accompanied by further reduction in CDI rate (RR: 0.394; 95% CI: 0.199-0.781). In a univariate Poisson model the CDI rate was associated with fluoroquinolone usage (RR: 1.086; 95% CI: 1.077-1.094). Conclusion: We conclude that in an environment where cephalosporin usage is already low, the reduction in fluoroquinolone usage was associated with an immediate, large, and significant reduction in CDI cases. (C) 2015 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:74 / 80
页数:7
相关论文
共 24 条
  • [1] Effects of ciprofloxacin on the expression and production of exotoxins by Clostridium difficile
    Aldape, Michael John
    Packham, Aaron Eugene
    Nute, Drew William
    Bryant, Amy Evelyn
    Stevens, Dennis Leroy
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 2013, 62 : 741 - 747
  • [2] Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model
    Baines, SD
    Freeman, J
    Wilcox, MH
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (06) : 974 - 982
  • [3] Case-control study of antibiotic use and subsequent Clostridium difficile -: Associated diarrhea in hospitalized patients
    Baxter, Roger
    Ray, G. Thomas
    Fireman, Bruce H.
    [J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2008, 29 (01) : 44 - 50
  • [4] Commission for Healthcare Audit and Inspection, 2006, INV OUTBR CLOSTR DIF
  • [5] Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK
    Delaney, J. A. Chris
    Dial, Sandra
    Barkun, Alan
    Suissa, Samy
    [J]. EMERGING INFECTIOUS DISEASES, 2007, 13 (05) : 761 - 763
  • [6] Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship
    Dellit, Timothy H.
    Owens, Robert C.
    McGowan, John E., Jr.
    Gerding, Dale N.
    Weinstein, Robert A.
    Burke, John P.
    Huskins, W. Charles
    Paterson, David L.
    Fishman, Neil O.
    Carpenter, Christopher F.
    Brennan, P. J.
    Billeter, Marianne
    Hooton, Thomas M.
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 44 (02) : 159 - 177
  • [7] Clostridium difficile-associated disease in a setting of endemicity:: Identification of novel risk factors
    Dubberke, Erik R.
    Reske, Kimberly A.
    Yan, Yan
    Olsen, Margaret A.
    McDonald, L. Clifford
    Fraser, Victoria J.
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 45 (12) : 1543 - 1549
  • [8] The Changing Epidemiology of Clostridium difficile Infections
    Freeman, J.
    Bauer, M. P.
    Baines, S. D.
    Corver, J.
    Fawley, W. N.
    Goorhuis, B.
    Kuijper, E. J.
    Wilcox, M. H.
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2010, 23 (03) : 529 - +
  • [9] Outbreak of Clostridium difficile infection in a long-term care facility:: Association with gatifloxacin use
    Gaynes, R
    Rimland, D
    Killum, E
    Lowery, HK
    Johnson, TM
    Killgore, G
    Tenover, FC
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 (05) : 640 - 645
  • [10] Clostridium difficile PCR Ribotype 078:: an emerging strain in humans and in pigs?
    Goorhuis, Abraham
    Debast, Sylvia B.
    van Leengoed, Leo A. M. G.
    Harmarms, Celine
    Notermans, Daan W.
    Bergwerff, Aldert A.
    Kuijper, Edward J.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (03) : 1157 - 1157